Moran said that clinicians have long observed “patients without previous psychiatric history” developing psychosis “in the setting of stimulant use.”
The study, which was funded by the National Institutes of Health, looked at insurance claims on more than 220,000 ADHD patients between the ages of 13 and 25 years old who had started taking amphetamines or methylphenidate between Jan. 1, 2004, and Sept. 30, 2015.
According to the study, researchers found that one out of every 486 patients started on an amphetamine developed psychosis that required treatment with antipsychotic medication. One in 1,046 patients started on methylphenidate developed psychosis.
The study showed that the development of psychosis appeared in people who had recently begun taking the amphetamines.
Moran stressed that “people who have been on a drug like Adderall for a long time, who are taking the drug as prescribed and are tolerating it well, are not likely to experience this problem (psychosis).”
The paper, “Psychosis with Amphetamine or Methylphenidate in Attention Deficit Disorder,” is set to be published on Thursday in the New England Journal of Medicine.